The ASX healthcare sector lost 6% in a single day on Wednesday, its worst session in years. The trigger was Cochlear (ASX:COH), which fell 40.7% to a decade-low of A$99.58 after slashing its profit guidance. The damage spread well beyond Cochlear itself, with CSL (ASX:CSL) down 5.7%, ResMed (ASX:RMD) off 2.5%, and most other healthcare names dragged lower in sympathy. For long-term investors, the question now is simple: where in the wreckage are there real bargains, and where are the risks still hiding?
Why the Whole Sector Got Punished
When a heavyweight cuts guidance this sharply, the market assumes everyone else is next. The fear is that weaker US consumer spending on discretionary healthcare could hit other premium-rated ASX names. We believe this fear is justified for some companies, but not for others. The selloff was indiscriminate, treating very different businesses as if they shared the same problem. That is exactly the kind of moment where careful investors find value, because the market is pricing in pain that will not actually arrive for every company.
CSL (ASX:CSL): The Cleanest Bargain in the Sector
CSL fell 5.7% to A$128.68, marking a nine-year low. The crucial point is that CSL’s blood plasma business has very little in common with Cochlear’s hearing implants. Cochlear sells discretionary devices that nervous consumers can put off. CSL sells life-saving plasma therapies that patients cannot delay. The valuation premium CSL traded on for years has been completely stripped out, with the price-to-earnings ratio compressed to roughly 14.7 times trailing earnings, near its lowest level in a decade. For long-term holders, paying a near-decade-low multiple for a global leader in plasma therapies looks like one of the better entry points in years.
Sonic Healthcare (ASX:SHL): The Defensive Play Most People Forgot
Sonic Healthcare runs pathology and diagnostics services, which are about as defensive as healthcare gets. People need blood tests regardless of how the economy feels, and Sonic’s revenue is largely insulated from the US consumer pressures that hit Cochlear. Sonic also pays a meaningful dividend, which becomes more attractive as the share price falls. It lacks the growth excitement of CSL, but it offers something investors badly need right now: predictability. For income-focused or conservative investors, this is the kind of name that quietly compounds while flashier stocks crash and recover.
Sigma Healthcare (ASX:SIG): A Different Kind of Healthcare Exposure
Sigma Healthcare is a pharmaceutical distributor and pharmacy operator following its merger with Chemist Warehouse. That gives it exposure to everyday pharmacy spending and prescription volumes, which barely flex with consumer sentiment. The Chemist Warehouse merger gave Sigma scale, distribution leverage, and a household-name retail brand. We believe Sigma is the kind of healthcare stock that benefits from being misclassified during sector-wide selloffs because its business model is closer to consumer staples than to medical devices.
The Investor’s Takeaway
Not every healthcare stock that fell on Wednesday is a bargain. ResMed, for instance, faces some of the same US discretionary headwinds that hit Cochlear. The important nuance is that masks and accessories make up around 35% of ResMed’s revenue and behave more like a recurring consumable than a one-off purchase, which gives it a defensiveness Cochlear lacks. Even so, ResMed’s premium device upgrade cycle is genuinely exposed. CSL, Sonic Healthcare, and Sigma Healthcare each offer cleaner value created by a selloff that did not bother to distinguish between them. For investors patient enough to look past the panic, this is where the opportunity sits.
